Alnylam

Heart drawn in the sand on the beach

BridgeBio touts case for acoramidis with post hoc study analysis

Acoramidis reduced the total number of all-cause mortality and recurrent cardiovascular hospitalization events by 42% compared to placebo.

Darren Incorvaia Sep 30, 2024 9:37am

Photo of a carnival ride that swings people in elevated chairs caught in motion

BridgeBio’s offshoot GondolaBio launches with $300M

Aug 21, 2024 11:36am

Alzheimers brain

Alnylam, Biogen build noise in Alzheimer's with gene silencing

Oct 26, 2023 8:51am

Role of hundred dollar bills on other bills

RNA biotech ADARx hauls in healthy $200M series C

Aug 9, 2023 10:17am

graphic art of a right hand signing something

Roche signs onto Alnylam's midstage hypertension med for $310M

Jul 24, 2023 11:00am

overcome ladder win beat advance obstacle maze

BridgeBio heart disease med vindicated with phase 3 victory

Jul 17, 2023 10:12am